Momenta Pharmaceuticals (MNTA) Upgraded at BidaskClub

BidaskClub upgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a hold rating to a buy rating in a research note released on Tuesday morning.

Several other analysts also recently commented on MNTA. Goldman Sachs Group initiated coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They set a neutral rating and a $18.00 price objective on the stock. Stifel Nicolaus restated a hold rating and set a $15.00 price objective (down from $22.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a hold rating to a buy rating and set a $20.00 price objective on the stock in a research report on Wednesday, October 4th. Barclays restated an equal weight rating and set a $16.00 price objective (down from $17.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Finally, JPMorgan Chase & Co. restated a hold rating and set a $14.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. Momenta Pharmaceuticals currently has an average rating of Hold and an average price target of $15.00.

Momenta Pharmaceuticals (MNTA) traded up $1.45 on Tuesday, reaching $15.75. 907,729 shares of the company’s stock traded hands, compared to its average volume of 815,466. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.90. The company has a market capitalization of $1,200.00, a P/E ratio of -19.69 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. The firm had revenue of $24.09 million for the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The company’s revenue was down 17.3% on a year-over-year basis. During the same period last year, the firm earned ($0.26) EPS. analysts predict that Momenta Pharmaceuticals will post -1.16 earnings per share for the current year.

In related news, Director Elizabeth Stoner sold 5,500 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the transaction, the director now directly owns 13,240 shares of the company’s stock, valued at $173,444. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Craig A. Wheeler sold 35,666 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Insiders have sold 49,505 shares of company stock valued at $685,923 over the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of MNTA. BlackRock Inc. grew its stake in Momenta Pharmaceuticals by 7.1% during the second quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock valued at $158,868,000 after acquiring an additional 626,415 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Momenta Pharmaceuticals by 186.4% in the 2nd quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock worth $13,476,000 after buying an additional 519,000 shares in the last quarter. FMR LLC grew its stake in shares of Momenta Pharmaceuticals by 3.3% in the 2nd quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock worth $188,015,000 after buying an additional 351,743 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Momenta Pharmaceuticals by 102.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 691,778 shares of the biotechnology company’s stock worth $11,691,000 after buying an additional 350,112 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Momenta Pharmaceuticals by 4.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after buying an additional 290,090 shares in the last quarter. 93.40% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2018/01/13/momenta-pharmaceuticals-mnta-upgraded-at-bidaskclub.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit